Skip to main content
. Author manuscript; available in PMC: 2021 Dec 16.
Published in final edited form as: ACS Bio Med Chem Au. 2021 Sep 10;1(1):31–43. doi: 10.1021/acsbiomedchemau.1c00021

Figure 6.

Figure 6.

Graphs of ELISspot disk counts comparing vaccinations of our TF-Ser(5)-MUC4- B13G-AuNP conjugate the TF-Ser(5)-MUC4-CRM197 conjugate and control B13G-AuNPs when panned for interferon-γ and IL-17 production. While the TF-Ser(5)-MUC4-CRM197 conjugate has an intense humoral response, the TF-MUC4 vaccine construct elicited a much stronger CD4+ T-cell response, whereas the control B13G-AuNPs consistently showed no response.